RVVTF Stock Chart & Stats
$0.02
>-$0.01(-3.52%)
At close: 4:00 PM EDT
$0.02
>-$0.01(-3.52%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.06
Previous CloseN/A
Volume39.13K
Average Volume (3M)308.74K
Market Cap
$7.46M
Enterprise Value$13.12M
Total Cash (Recent Filing)$22.66K
Total Debt (Recent Filing)$70.77K
Price to Earnings (P/E)―
Beta-1.97
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding418,564,270
10 Day Avg. Volume297,847
30 Day Avg. Volume308,738
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market Cap1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.62K
Enterprise Value/Ebitda-1.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery low absolute debt reduces interest burden and preserves flexibility for a development-stage biotech. Over a 2-6 month horizon, minimal leverage lowers bankruptcy risk and gives management room to pursue partnerships or milestone-based financing without large fixed debt servicing costs.
Improving Cash Burn TrendAn improving operating cash flow trend indicates the company is moderating cash burn, which can materially reduce near-term financing pressure. If sustained, lower burn supports runway extension and reduces dilution risk, improving the firm's ability to advance clinical programs over the coming months.
Focused Therapeutic PipelineA clear focus on therapeutic development (psilocybin and repurposed drugs) provides a defined business model and potential high-value binary catalysts (trials, regulatory milestones, partnerships). Structural upside from successful development or licensing deals supports long-term value creation if clinical progress continues.
Bears Say
No Commercial RevenueThe company has no commercial revenue and negative gross profit, meaning operations are entirely development-funded. Without product sales, the business cannot self-sustain operating costs, leaving it dependent on external capital and creating persistent risk to funding pipelines over the medium term.
Negative Stockholders' EquityA negative equity position reflects accumulated losses and weakens balance sheet credibility with lenders and partners. Over several months this constrains financing options, may force dilutive equity raises or onerous terms, and reduces the firm’s cushion against operational setbacks in development programs.
Persistent Negative Cash FlowSustained negative operating and free cash flows indicate reliance on financing to fund R&D and operations. This structural cash deficit increases dilution and execution risk, and limits the company's ability to scale or respond to trial setbacks without securing additional capital or strategic partnerships.
Revive Therapeutics News
RVVTF FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <$0.01 and its highest was $0.06 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is $7.46M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is Oct 26, 2026 which is in 84 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Jun 01, 2026. The company reported >-$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-$0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of >-$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in RVVTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.